Form 4: Onconetix Director Andrew John Oakley Reports Acquisition of Restricted Stock Units

Director Andrew John Oakley reports acquisition of 1,709 restricted stock units in Onconetix, Inc.

Summary

• On March 23, 2025, Andrew John Oakley, a director of Onconetix, Inc., reported the acquisition of 1,709 restricted stock units (RSUs).
• These RSUs will be settled in shares of common stock with a par value of $0.00001.
• The RSUs fully vest on August 31, 2025.
• Following the transaction, Oakley beneficially owns 1,709 shares, including unvested RSUs.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The acquisition of RSUs could be seen as slightly positive, but it's a routine event.

Positives

• The acquisition of restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of RSUs by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Form 4, restricted stock units, Onconetix, director, Oakley, beneficial ownership, ONCO